GNH USA

Europe — EMA

Mirabegron Glenmark

GNH USA supplies Mirabegron Glenmark (Mirabegron), a β3‑adrenergic receptor agonist for overactive bladder, urinary urgency and frequency.

Mirabegron

Request sourcing

1
Pack/s

What is Mirabegron?

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Mirabegron used for?

Mirabegron is used to manage overactive bladder, a condition characterized by urinary urgency, frequency, and incontinence.

- Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the intensity and frequency of sudden urges. - Urinary frequency: decreases the number of daytime voids.

What are the side effects of Mirabegron?

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dry mouth - Constipation - Hypertension - Headache - Nasopharyngitis - Urinary tract infection

Serious or Rare Side Effects: - Acute urinary retention - Severe hypertension - Tachycardia - Angioedema - Anaphylaxis - Renal impairment

What precautions apply to Mirabegron?

Before prescribing mirabegron, clinicians should evaluate several safety factors.

- Renal function: assess baseline renal function and adjust if necessary. - Hepatic impairment: use with caution in patients with severe liver disease. - Blood pressure: monitor regularly as mirabegron may increase systolic and diastolic pressure. - Drug interactions: review concomitant medications that affect adrenergic pathways. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

What does Mirabegron interact with?

Mirabegron can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron exposure. - Anticholinergic agents: combined effect may worsen urinary retention. - Nitrates: potential for additive hypotensive effect.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood pressure control. - Antihypertensives: monitor for additive blood pressure increase. - Warfarin: monitor INR as mirabegron may alter metabolism.

Frequently asked questions

What is Mirabegron Glenmark used for?+
Mirabegron Glenmark is prescribed to treat symptoms of overactive bladder, including urinary urgency, increased frequency of urination, and urge incontinence. By improving bladder storage capacity, it helps patients regain better control over their urinary habits and reduce disruptive episodes.
How does mirabegron work?+
Mirabegron works by selectively activating β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation raises cyclic AMP levels, causing smooth‑muscle relaxation, increased bladder capacity, and reduced involuntary contractions that trigger urgency and frequency.
What is the usual dose of mirabegron?+
The appropriate dose of mirabegron is determined by the prescribing clinician based on the patient’s medical condition, renal function, and response to therapy. The prescriber will select the starting dose and may adjust it during follow‑up visits to achieve optimal symptom control.
Is mirabegron safe during pregnancy or breastfeeding?+
Safety data for mirabegron in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.
How do I order Mirabegron Glenmark from GNH USA?+
To order Mirabegron Glenmark, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does mirabegron compare with antimuscarinic bladder drugs?+
Mirabegron belongs to a different therapeutic class than antimuscarinic agents. While antimuscarinics block muscarinic receptors and often cause dry mouth or constipation, mirabegron activates β3‑adrenergic receptors, typically resulting in a lower incidence of anticholinergic side effects but may raise blood pressure in some patients.
How should Mirabegron Glenmark be stored and handled?+
Store Mirabegron Glenmark at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.
How is Mirabegron Glenmark administered?+
Mirabegron Glenmark is taken orally as a whole tablet, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider, typically once daily at the same time each day.
What are the most serious risks associated with mirabegron?+
The most serious risks include acute urinary retention, severe hypertension, tachycardia, angioedema, anaphylactic reactions, and renal impairment. Patients should be educated to seek immediate medical attention if they experience difficulty urinating, a sudden rise in blood pressure, rapid heartbeat, swelling of the face or throat, or signs of kidney dysfunction.
Who should not use mirabegron?+
Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, significant urinary retention, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with moderate renal impairment or those taking medications that strongly inhibit CYP2D6.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mirabegron
Route
Oral Use
Manufacturer
Glenmark Arzneimittel Gmbh
Origin
EU

Related products

Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 50 mg/1

Myrbetriq 50 mg/1

Mirabegron · 50 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA